Company Overview and News

 
Natco Pharma Limited - Shareholders meeting

2018-09-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
NATCOPHARM 524816

 
Natco Pharma Limited - Updates

2018-09-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
NATCOPHARM 524816

 
Pullback rally can propel Nifty to 11,600; Natco Pharma among 3 stocks which can give up to 12% return

2018-09-12 moneycontrol
Nifty extended its corrective Wave A, B and C and the ongoing wave being corrective wave 'C'. Moreover, it is approaching 161.8 percent Fibonacci extension level placed at 11,264 which also happened to be the 50-DMA.
ABB CARBORUNIV NATCOPHARM 524816 500002 ABBDY 513375

11
Celgene Vs. AbbVie: The 2 Cheapest Large Cap Pharma Stocks

2018-08-31 seekingalpha
Wall Street is more bullish on Celgene and expects 19% upside potential based on an average price target of $112.73.
NATCOPHARM 524816 CELG ABBV ABBV

 
Panacea inks deal with Natco, Breckenridge

2018-08-27 thehindubusinessline
Panacea Biotec on Monday inked a tripartite pact with Natco Pharma and Breckenridge Pharmaceutical Inc to manufacture and supply Azacitidine injection, a chemotherapy drug, for the US market. Under its terms, Natco has provided the technology for manufacturing Azacitidine to Panacea Biotec’s Baddi facility. Panacea will manufacture and supply the product, which will be marketed and distributed by Breckenridge in the US.
PANACEABIO 570002 NATCOPHARM LICHSGFIN FRLDVR FRL 524816 523574 LHFLY 531349 500253

 
Panacea inks pact with Natco, Breckenridge for cancer drug

2018-08-27 moneycontrol
Panacea Biotec today said it has inked a tripartite pact with Natco Pharma and Breckenridge Pharmaceutical Inc to manufacture and supply of Azacitidine injection, a chemotherapy drug, for the US market. As per the terms of agreement, Natco has provided the technology for manufacturing Azacitidine to Panacea Biotec's Baddi facility.
PANACEABIO NATCOPHARM 524816 531349

3
Is The Bottom In For Celgene?

2018-08-14 seekingalpha - 1
Celgene Corporation (CELG) has had a less than ideal past 10 months. Hitting highs in early October 2017 of $147.17, the stock fell to $74.13 in May 2018. A 50 percent drop, or a 50 percent pop, is standard for many of the smaller biotechs I cover, but not normally, the domain of a $60B biopharmaceutical giant like CELG. A lot of the factors that led to the drop of CELG are in the past now, and the focus of this article isn't to dwell on those.
CELGZ 524816 ARNA RDY NATCOPHARM CELG RCPT MS

1
Dr Reddy#39;s eyeing European market for cancer drug

2018-08-13 moneycontrol - 1
Natco Pharma today said its co-development and marketing partner Dr Reddys Laboratories Ltd has filed an application with the European Medicines Agency for marketing a cancer drug in Europe.
RDY NATCOPHARM 524816

 
Natco Pharma Limited - Press Release

2018-08-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
NATCOPHARM 524816

 
Natco Pharma Q1 net profit up 93% to Rs 181 crore

2018-08-08 moneycontrol
Drug firm Natco Pharma today reported a 93.27 percent rise in its consolidated net profit to Rs 181.1 crore for the quarter ended June 30 mainly on account of robust sales.
NATCOPHARM 524816

 
Natco Pharma Limited - Dividend

2018-08-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
NATCOPHARM 524816

 
Natco Pharma Limited - Record Date

2018-08-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
NATCOPHARM 524816

 
Cipla, Indian Bank, HCC, Lupin, 8K Miles results

2018-08-07 thehindubusinessline
Over 175 companies including 8K Miles, 20 Microns, AB Capital, Asahi Songwon, Balrampur Chini, BEML, BPCL, Blue Star, Cipla, City Union Bank, EID Parry, Emami Infra, Forbes, Future Consumer, Goodyear, Greenply, HCC, HPCL, Hikal, Hindustan Motors, IVP, Indian Bank, Indian Hume, Jamna Auto, Kanoria Chem, Lakshmi Electrical, Lupin, Natco Pharma, NALCO, NMDC, Phoenix, PNB Housing, Siemens, Thermax, Trent and UFO Moviez will declare their April-June results on Tuesday.
HNDNF INDIANB 532210 HINDALCO NATCOPHARM CUB 524816 532814 500500 HINDMOTORS 500440

 
Natco Pharma Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
NATCOPHARM 524816

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...